Studies in several countries show a trend toward reduced age-related macular degeneration-related blindness, thanks to the widespread introduction of anti-VEGF injection therapies. However, not all countries are doing equally well.
“We have a powerful weapon, but not all health care systems seem to be able to make the best use of it. Regulatory obstacles and inefficient management of human and technological resources hinder regular access to therapies and lead to suboptimal outcomes,” Paolo Lanzetta, MD, said in an interview with Healio/OSN.
In a review published in Graefe’s